PSMA PET/CT in Detecting Esophageal Cancer and Hepatocellular Carcinoma. A Report of Two Cases

Rami Chatta; Hina Shah; Saurabh Pallod

doi:10.1097/RLU.0000000000005901

PSMA PET/CT in Detecting Esophageal Cancer and Hepatocellular Carcinoma. A Report of Two Cases

Clin Nucl Med. 2025 Apr 18. doi: 10.1097/RLU.0000000000005901. Online ahead of print.

Authors

Rami Chatta¹, Hina Shah¹, Saurabh Pallod²

Affiliations

¹ Department of Radiology, Harvard Medical School, Brigham and Women's Hospital.
² Department of Nuclear and Molecular Imaging, Harvard Medical School, Dana Farber Cancer Institute, Boston MA.

PMID: 40247467
DOI: 10.1097/RLU.0000000000005901

Abstract

Prostate-specific membrane antigen (PSMA) PET/CT has improved the diagnosis, staging, and detection of recurrent and metastatic prostate cancer. Nevertheless, PSMA uptake has also been observed in non-prostatic conditions, which underscores the need to explore its broader applications and refine our understanding of its specificity in diverse clinical contexts. In cases of uptake in atypical locations, further workup is warranted to avoid premature conclusions of metastatic prostate disease. We report two cases of PSMA PET uptake: the first involves esophageal cancer, and the second details two synchronous malignancies-hepatocellular and esophageal cancer.

Keywords: PET/CT; PSMA; esophageal cancer; hepatocellular carcinoma; prostate cancer.